Navigation Links
Lamictal as add-on therapy for children with epilepsy

The U.S. Food and Drug Administration has approved GlaxoSmithKline's new drug Lamictal (lamotrigine) as an addition for children whose partial seizures are inadequately controlled on their existing therapy. This new indication is an expansion of the //already-approved indications for adjunctive use in adults with partial seizures, and for the generalized seizures of Lennox-Gastaut Syndrome in children two years of age and older.

Partial seizures are the most common type of epilepsy and they begin with abnormal electrical activity in a particular location in the brain. The effect of these seizures include lip smacking, a dazed state or jerking movements of certain body parts.

The approval of the drug was based on a clinical study that demonstrated the efficacy of the drug as add-on therapy in pediatric patients who were still having frequent partial seizures (at least four per month) despite optimal doses of other anti-epilepsy drugs (AEDs). The study was a 18 week placebo controlled study in which 200 patients aged between 2 and 15 years, who were still having frequent seizures despite use of other AEDs, were randomized to treatment with Lamictal or placebo added to their current AED regimen of up to two drugs (Lamictal: 99, placebo: 101). The results showed significant reductions in the frequency of all partial seizures in children and adolescents with epilepsy when Lamictal was added to their AED regimen.

Michael Duchowny, director of the Comprehensive Epilepsy Program at Miami Children's Hospital said that Lamictal would be a welcome addition as FDA-approved therapies for children with epilepsy are limited and any clinically proven medication which can effectively control seizures in children would be an important new option to manage this condition.


'"/>




Page: 1

Related medicine news :

1. GlaxoSmithKline - Changes Lamictal(R) Label Appearance and Packaging
2. Analysis Shows Lamictal As An Effective Additional Therapy For Treatment of Grand Mal Seizures
3. FDA Decision Encourages Lamictal Generics
4. Acupuncture May Help Chemotherapy Side Effects
5. Antioxidants protect health tissue in people undergoing radiation therapy.
6. Distraction therapy found very effective in postoperative patients
7. Acupuncture superseeds massage therapy for short term relief of pain
8. Ovarian cancer in relationship with Hormone therapy
9. New therapy better at increasing bone density
10. Gene therapy - Aim to improve blood flow
11. Gene therapy restores sight
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/28/2016)... ... May 28, 2016 , ... May 26, 2016- In ... Arts Fighting Challenge with theme event of “K Warriors” on June 4, 2016 at ... , The event is sponsored and hosted by Shaolin Institute and sanctioned by ...
(Date:5/27/2016)... ... 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue Shield ... (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields and ... of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health and ...
(Date:5/27/2016)... NY (PRWEB) , ... May 27, 2016 , ... ... casual readers, this installment is bolstered by inspiring human-interest stories, courtesy of awareness-driven ... tech within the industry, from leading advocates, associations and industry leaders such as ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... in scholarships to students studying complementary medicine. Allison Outerbridge is this year’s ... her award on May 18 at the university’s Student Leadership Awards ceremony. , ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and 3M ... to court documents and SEC filings. A jury has returned a verdict ... Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... YORK , May 27, 2016 ... biotechs, drug manufacturers, health insurance companies all falling under ... small healthcare companies. While not often talked about, these ... The United States is by far ... world. Advanced Medical Isotope Corp. (OTC: ADMD), Nutranomics Inc. ...
(Date:5/26/2016)... -- TARE (Transarterial Radio-embolization) Using Yttrium-90 ... Overall Decreased Use of Hospital Resource ... healthcare company, has today announced the publication of ... ISPOR (International Society for Pharmacoeconomics and Outcomes Research), ... yttrium-90 glass microspheres is associated with cost savings ...
(Date:5/25/2016)... , May 25,2016 ... the near-infrared Cellvizio platform for urological and surgical ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... regulatory milestone in the US with the 12 ... and Drug Administration (FDA). This new FDA clearance ...
Breaking Medicine Technology: